$13.45
+0.15
(+1.13%)▲
Live
5.95%
Downside
Day's Volatility :7.26%
Upside
1.39%
55.17%
Downside
52 Weeks Volatility :78.73%
Upside
52.56%
Period | DAY ONE BIOPHARMACEUTICALS I | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.42% | 0.7% | -6.8% |
6 Months | -37.32% | -8.3% | -6.0% |
1 Year | 102.74% | -1.9% | -4.6% |
3 Years | -38.85% | 25.3% | 25.9% |
Market Capitalization | 978.5M |
Book Value | $4.08 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.2 |
Wall Street Target Price | 39.56 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -34.88% |
Return On Equity TTM | -56.01% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -165.0M |
Diluted Eps TTM | -2.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.48 |
EPS Estimate Next Year | -2.05 |
EPS Estimate Current Quarter | -0.59 |
EPS Estimate Next Quarter | -0.6 |
What analysts predicted
Upside of 194.13%
Sell
Neutral
Buy
DAY ONE BIOPHARMACEUTICALS I is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() DAY ONE BIOPHARMACEUTICALS I | -8.09% | -37.32% | 102.74% | -38.85% | -38.85% |
![]() Moderna, Inc. | -4.27% | -29.63% | -10.94% | 105.39% | 586.61% |
![]() Regeneron Pharmaceuticals, Inc. | -8.82% | -3.37% | 11.63% | 22.7% | 139.69% |
![]() Seagen, Inc. | -1.74% | 61.71% | 45.87% | 23.07% | 217.59% |
![]() Vertex Pharmaceuticals Incorporated | -6.21% | 0.88% | 20.1% | 12.88% | 112.8% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() DAY ONE BIOPHARMACEUTICALS I | 3.54 | NA | NA | -2.48 | -0.56 | -0.35 | 0.0 | 4.08 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.15 | 26.15 | 0.41 | 14.62 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() DAY ONE BIOPHARMACEUTICALS I | Buy | $978.5M | -38.85% | 3.54 | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 586.61% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 139.69% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.7B | 217.59% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.8B | 112.8% | 26.15 | 35.4% |
FMR Inc
RA Capital Management, LLC
Franklin Resources Inc
Vanguard Group Inc
Canaan Partners XI LLC
BlackRock Inc
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.
Organization | DAY ONE BIOPHARMACEUTICALS I |
Employees | 125 |
CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Industry | Healthcare |
ISHARES GSCI COMMODITY DYNAM
$25.58
+2.24%
ALPHA CAPITAL HOLDCO CO-A
$2.21
-1.34%
ESGEN ACQUISITION CORP.
$10.86
+0.0%
NuShares ESG Mid-Cap Value ETF
$27.65
+0.47%
PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF
$18.00
+1.24%
BLACKROCK MUNIVEST FUND
$6.67
+0.6%
TELESAT CORP
$7.06
+1.0%
FIRST TRUST MATERIALS ALPHAD
$58.46
+1.42%
James River Group Holdings Ltd
$19.07
-0.37%